Table 5 Three-month recurrent VTE, bleeding, and mortality incidences in adult patients in EINSTEIN DVT and EINSTEIN PE [10,11,12]
Rivaroxaban n/N (%; 95% CI) | Standard anticoagulation n/N (%; 95% CI) | Absolute risk difference (95% CI) | Hazard ratio (95% CI) | |
|---|---|---|---|---|
Recurrent VTE | 69/4150 (1.7; 1.3–2.1) | 82/4131 (2.0; 1.6–2.5) | 0.3 (−0.3–0.9) | 0.82 (0.60–1.13) |
Major bleeding | 28/4130 (0.7; 0.5–1.0) | 49/4116 (1.2; 0.9–1.6) | 0.5 (0.1–0.9) | 0.55 (0.35–0.88) |
Major and clinically relevant nonmajor bleeding | 286/4130 (6.9; 6.2–7.7) | 287/4116 (7.0; 6.2–7.8) | 0.0 (−1.1–1.1) | 0.98 (0.83–1.16) |
Mortality | 53/4150 (1.3; 1.0–1.7) | 61/4131 (1.5; 1.1–1.9) | 0.2 (−0.3–0.7) | 0.81 (0.56–1.17) |